New Approach to Palliative Radiation Plans Reduces the Amount of Time Patients Spend in Treatment Centers
Using diagnostic CT scans to create palliation plans may save time and improve the patient experience.
Study Shows 5 Key Determinants of Health Drive Outcomes in Hematologic Malignancies
Although survival is improving overall, disparities continue to grow.
TROPiCS-02 Final OS Analysis Shows Superior Outcomes With Sacituzumab Govitecan For HR+/HER2– Breast Cancer
Sacituzumab govitecan improved overall survival vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.
Hyperthermic Intraperitoneal Chemotherapy is Not Associated With Worse HRQOL in Ovarian Cancer
Patients with ovarian cancer who received hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not experience worse health-related quality of life, according to investigators.
Lenvatinib Plus Pembrolizumab Elicits Durable Responses in Patients With Endometrial Cancer
In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.
Adjuvant Nivolumab Continues to Minimize Recurrence for Patients With Muscle-Invasive Urothelial Cancer
Extended follow-up of the CheckMate 274 trial showed continued efficacy with nivolumab in patients with muscle-invasive urothelial cancer who had undergone radical resection.
Camizestrant Emerges As A Potentially Effective Oral SERD for Patients With HER2-Negative Advanced Breast Cancer
Camizestrant doubled progression-free survival compared with fulvestrant in patients with estrogen receptor–positive, HER2-negative advanced breast cancer.
3.5-Year Follow-Up Finds Pembrolizumab/Etoposide Combo Still Effective in Untreated ES-SCLC
Patients with treatment-naive extensive-stage small cell lung cancer showed encouraging clinical responses with pembrolizumab and etoposide after multiple years of follow-up.
Atezolizumab Signals OS Improvement in Patients with Resected NSCLC
Phase 3 findings from the IMpower010 trial show that patients with resected non–small cell lung cancer may achieve an overall survival benefit with atezolizumab.
Liso-cel Exhibits Durable Responses in Relapsed-Refractory Large B-Cell Lymphoma
Patients with relapsed/refractory large B-cell lymphoma continued to derive benefit from lisocabtagene maraleucel after 2 years of follow-up.
Axi-cel Sustains Long-Term Survival Rates in Relapsed/Refractory Large B-Cell Lymphoma
Patients with relapsed or refractory large B-cell lymphoma experienced improved overall survival following treatment with axicabtagene ciloleucel.
Maintenance Selinexor Yields Survival Benefit in Advanced or Recurrent Endometrial Cancer
Selinexor demonstrated impressive efficacy in extending progression-free survival among patient with advanced or recurrent endometrial cancer, particularly among patients with wild-type p53 endometrial cancer.
Pembrolizumab Plus Sacituzumab Govitecan Yields Encouraging Antitumor Activity in Metastatic Urothelial Cancer
Adding sacituzumab govitecan to second-line pembrolizumab garnered promising antitumor activity among patients with checkpoint inhibitor–naïve metastatic urothelial cancer.
Genomic Alterations in Primary Breast Cancer May Increase Risk of Secondary Uterine Cancer in Patients Receiving Tamoxifen
PI3K-pathway mutations may predict an increased risk of secondary uterine cancer in patients receiving tamoxifen to treat primary breast cancer.
Low-Dose Venetoclax Induces Antitumor Activity in Subsets of AL Amyloidosis, Myeloma
Overall, 71% of patients with AL amyloidosis and 33% of those with heavily pretreated multiple myeloma achieved a partial response or greater after receiving treatment with low dose venetoclax.
African Ancestry Associated With Increased Prostate Cancer Risk
Germline variation may cause men of African descent to have a higher risk of prostate than men of European descent.
Visceral Fat Index Score Questions Obesity-Survival Connection in Early-Stage Lung Cancer
Whether or not obesity should be considered a risk factor for non-small lung cancer might be determined by how it is measured.
Diverse Patient Population Favors Immediate Therapy After Receiving Genomic Prostate Score
Patients with favorable-risk prostate cancer tended to move away from active surveillance to initiating treatment after receiving their Oncotype DX Genomic Prostate Score.
Race, Socioeconomic Factors May Impact Survival Outcome in Limited-Stage Small Cell Lung Cancer
African American, Asian, and Hispanic patients with limited-stage small cell lung cancer displayed superior survival outcomes compared with White patients, indicating that race might be linked with survival in this disease.
Adjuvant Radiation Therapy Associated with Reduced Risk of Death in High-Risk Prostate Cancer
Adjuvant radiation therapy treatment yielded strong results in reducing all-cause mortality in patients with high-risk prostate cancer.
Expert Talks Safety Considerations in 4-Drug Myeloma Regimen
Consider options like prophylactic medications and optimal fluid administration when giving a 4-drug regimen to treat patients with multiple myeloma, one expert says.
Tackle Racial Inequalities in Cancer Care
Cultural competence, multidisciplinary efforts with diverse faculty, and high-risk screening programs could help to address critical gaps and cancer disparities.
Whole-Genome Sequencing Helps Predict MGUS and Smoldering Myeloma Outcomes
Whole-genome sequencing may hold the answers for patients with myeloma precursor conditions.
Individualized Treatment May Improve Outcomes in Gastroesophageal Cancer
Personalized and adaptable treatment regimens seem to be the way forward in treating gastroesophageal cancer.
Shorter Adjuvant Trastuzumab Has Long-Term Benefits for HER2+ Breast Cancer
A 9-week trastuzumab regimen may be favorable for patients with HER2-positive early breast cancer who have low and intermediate risk factors.
Next Up in SCLC: Immunotherapy Combinations
New immunotherapy combinations are being explored in the small cell lung cancer space.
Reduce Recurrence in Early-Stage NSCLC
Edward S. Kim, MD, highlights the impact of osimertinib in the treatment of patients with EGFR-mutant non–small cell lung cancer, next steps with the agent, and the importance of early genetic testing to provide personalized care.
HRD Testing Expands, But Still Lacks Standardization in Ovarian Cancer
Two tests for homologous recombination deficiency have been FDA approved for patients with ovarian cancer, including myChoice CDx and FoundationOne CDx, and they produce important information that can be used to guide treatment decisions.
Breast Cancer Surgery in a Pandemic: What's the Best Approach?
A breast surgeon discusses the best practices for breast cancer surgery during the COVID-19 pandemic.
Cancer Screening and Diagnoses in Northeast Return to Pre-COVID-19 Levels
Although cancer screening rates and ensuing diagnoses dropped significantly during the height of the COVID-19 pandemic, testing rates from June 2020 through September 2020 have nearly returned to pre-pandemic levels.
Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
2 Clarke Drive Cranbury, NJ 08512